The global demand for Infliximab Market is presumed to reach the market size of nearly USD 74.78 MN by 2028 from USD 38.45 MN in 2021 with a CAGR of 8.67% under the study period 2022 - 2028.
Infliximab is a kind of monoclonal antibody drug. It is a prescription drug used for treating a number of autoimmune diseases. It acts as an immunosuppressant and treats rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and bowel diseases like ulcerative colitis and Crohn’s disease. This biological therapy works by blocking the action of TNF-alpha (tumor necrosis factor alpha), a chemical which triggers inflammation in the body. It helps to reduce swelling. Usually, it is recommended for patients who do not respond to or cannot tolerate other treatments. It is infused intravenously over 2 hours in a hospital setting and can be used in adult and paediatric patients.
Market Dynamics
The Infliximab market is anticipated to exhibit significant growth in the forecasted timeline. The key factor driving the market are increasing incidence of autoimmune diseases like rheumatoid arthritis and plaque psoriasis. The rising pateints with Crohn’s disease and ulcerative colitis is another major factor contributing towards market growth. The target market will be favoured by early patent expiration of the drug. Other major factors fuelling market growth are discounted price of branded drugs and quick action due to intravenous infusion. In addition, launching of biosimilars and its affordability will further boost the market. However, the aftereffect of Infliximab may hamper its market growth during the assessment period.
The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of infliximab. The growth and trends of infliximab industry provide a holistic approach to this study.
Market Segmentation
This section of the infliximab market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Type
- Inflectra
- Renflexis
- Others
By Route Of Administration
- Subcutaneous
- Intravenous
- Parenteral
By Molecule Type
- Monoclonal Antibodies
- Peptide
- Protein
- Small Molecule
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
Regional Analysis
This section covers the regional outlook, which accentuates current and future demand for the Infliximab market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
Global Infliximab Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the infliximab market include Amgen Inc., Pfizer Inc., Eli Lilly and Company, Novartis AG, F. Hoffmann-La Roche Ltd, Eisai Co., Ltd, Allergan, Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Endo International plc, Sun Pharmaceutical Industries Ltd, Mylan N.V., Apotex Inc., and Biocad, and others. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
